NeuroEPO & NeuralCIM® Neuroprotective Therapy Explained

What Is NeuroEPO?

NeuroEPO is a Cuban-developed neuroprotective medication based on recombinant human erythropoietin (EPO) — engineered specifically to cross the blood-brain barrier and deliver neuroprotective effects directly to brain tissue.

While erythropoietin is commonly known as a hormone that stimulates red blood cell production, research by Cuba's Center for Genetic Engineering and Biotechnology (CIGB) revealed that EPO also has powerful neuroprotective properties — protecting neurons from damage, reducing inflammation, and promoting cellular survival in the brain.

NeuroEPO differs from conventional EPO in its formulation: it is designed to achieve therapeutic concentrations in the central nervous system, making it a candidate for treating neurodegenerative conditions including Alzheimer's disease.

How NeuralCIM® Works

NeuralCIM® is the brand name under which NeuroEPO-based therapy is administered within Cuba's comprehensive Alzheimer's treatment programs. The therapy aims to:

1. Protect neurons from oxidative stress and inflammation — key drivers of Alzheimer's progression. 2. Promote neuroplasticity — the brain's ability to form new neural connections, supporting cognitive rehabilitation. 3. Reduce neuronal apoptosis — preventing programmed cell death in vulnerable brain regions. 4. Support angiogenesis — improving blood flow to brain tissue.

NeuralCIM® is administered as part of an integrated protocol that combines the neuroprotective medication with intensive cognitive rehabilitation, occupational therapy, and neuropsychological support. It is not a standalone cure — it works synergistically with the rehabilitation components of Cuba's multidisciplinary program.

Clinical Research & Evidence

NeuroEPO has been investigated in preclinical and clinical studies by Cuban research institutions. Studies have explored its neuroprotective effects in models of Alzheimer's disease, stroke, and other neurological conditions.

It is important to note that NeuroEPO/NeuralCIM® is part of an emerging area of neuroprotective research. While Cuban clinical experience and published studies are encouraging, international patients should understand that:

• NeuroEPO is administered under strict medical protocols in accredited Cuban facilities • Treatment is personalized based on each patient's diagnosis and stage • Results vary by individual — no therapeutic outcome is guaranteed • The therapy is part of a comprehensive program, not a standalone treatment • Eligibility is determined by a multidisciplinary medical review

Patients receive detailed information about the therapy, its intended effects, and the treatment protocol before beginning the program.

The Integrated Treatment Protocol

NeuralCIM® therapy is delivered within Cuba's multidisciplinary Alzheimer's program, which typically includes:

• Neuroprotective medication (NeuralCIM®) — administered according to the specialist-determined protocol • Intensive cognitive rehabilitation — 4-6 hours of daily therapy targeting memory, attention, language, and executive function • Occupational therapy — maintaining daily living skills and independence • Neuropsychological support — addressing mood, behavior, and coping strategies • Physical therapy — maintaining mobility and overall health • Caregiver education and family support — training families to support recovery at home

This intensive, coordinated model — practiced at Cuban neuroscience centers — is what distinguishes the Cuban approach. The combination of biotechnology innovation with comprehensive rehabilitation aims to maximize cognitive preservation and quality of life.